Verve Therapeutics, Inc.
(NASDAQ : VERV)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. -0.07%243.141.5%$878.54m
MRNAModerna, Inc. 4.37%149.090.0%$806.04m
VRTXVertex Pharmaceuticals, Inc. 0.36%282.791.9%$481.53m
GILDGilead Sciences, Inc. -0.14%61.721.0%$474.71m
REGNRegeneron Pharmaceuticals, Inc. -0.17%590.142.6%$470.87m
NVAXNovavax, Inc. 9.89%56.5275.7%$437.96m
ILMNIllumina, Inc. 2.25%188.503.3%$343.40m
SNSSSunesis Pharmaceuticals, Inc. -6.19%3.640.7%$254.45m
BIIBBiogen, Inc. 1.21%206.401.8%$240.94m
BNTXBioNTech SE 4.60%155.960.0%$195.77m
CRSPCRISPR Therapeutics AG 2.51%62.300.6%$164.12m
BMRNBioMarin Pharmaceutical, Inc. 0.85%83.584.2%$117.18m
EXASEXACT Sciences Corp. 3.02%40.5817.7%$93.68m
IOVAIovance Biotherapeutics, Inc. 2.54%11.320.0%$90.34m
TECHBio-Techne Corp. 0.19%347.284.5%$89.78m

Company Profile

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan and Burt A. Adelman in 2018 and is headquartered in Cambridge, MA.